NEW YORK – BGI Genomics has seen growth in several areas of its core diagnostic testing business during the first half of 2021 and is working on upgrading its tests in reproductive health.
Late last month, the publicly traded clinical BGI prenatal test and research services arm of China's BGI Group reported that total revenues in H1 declined due to decreasing demand for COVID-19 testing, while its cancer prevention and control, reproductive health including its flagship NIFTY noninvasive prenatal test, and infection prevention and control businesses grew.